Woehrle, H.
Schoebel, C.
Oldenburg, O.
Young, P.
Fietze, I.
Ficker, J. H.
Bischoff-Everding, C.
Libutzki, B.
Arzt, M.
Funding for this research was provided by:
Universitätsklinikum Regensburg
Article History
First Online: 12 August 2020
Compliance with ethical guidelines
:
: H. Woehrle is a paid consultant to ResMed and has received research grants. C. Schoebel reports personal fees from ResMed. O. Oldenburg reports grants and personal fees from ResMed and Sorin/Respircardia. P. Young reports personal fees from Sanofi Genzyme, Biomarin, UCB Pharma, Medice, ResMed, Loewenstein Medical and Vanda, and grants from Lowensteinstiftung and the German Ministry of Education and Science (BMBF), outside the submitted work. I. Fietze reports grants from ResMed, Philips, Fisher & Paykel, Hoffrichter, Löwenstein Medical and Weinmann, and personal fees from ResMed, outside the submitted work. J.H. Ficker reports personal fees and non-financial support from ResMed and Weinmann, outside the submitted work. C. Bischoff-Everding is CEO of HGC. B. Libutzki is employed at HGC, a German healthcare consulting firm that received honoraria from ResMed for health economic outcome research. M. Arzt reports personal fees from Boehringer Ingelheim, Jazz Pharmaceuticals, Inspire and NRI; grants and personal fees from ResMed and Philips Respironics as well as grants from the Else Kröner-Fresenius-Stiftung and the ResMed Foundation outside the submitted work.
: For this article no studies with human participants or animals were performed by any of the authors. All studies performed were in accordance with the ethical standards indicated in each case.